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Abstract
Microvascular inflammation occurs during sepsis and the endogenous opioid-like peptide nociceptin/orphanin FQ (N/
OFQ) is known to regulate inflammation. This study aimed to determine the inflammatory role of N/OFQ and its
receptor NOP (ORL1) within the microcirculation, along with anti-inflammatory effects of the NOP antagonist
UFP-101 (University of Ferrara Peptide-101) in an animal model of sepsis (endotoxemia).
Male Wistar rats (220 to 300 g) were administered lipopolysaccharide (LPS) for 24 h (-24 h, 1 mg kg-1; -2 h, 1 mg
kg-1 i.v., tail vein). They were then either anesthetised for observation of the mesenteric microcirculation using
fluorescent in vivo microscopy, or isolated arterioles (~200 µm) were studied in vitro with pressure myography.
200 nM kg-1 fluorescently labelled N/OFQ (FITC-N/OFQ, i.a., mesenteric artery) bound to specific sites on the
microvascular endothelium in vivo, indicating sparse distribution of NOP receptors. In vitro, arterioles (~200 µm)
dilated to intraluminal N/OFQ (10-5M) (32.6 + 8.4%) and this response was exaggerated with LPS (62.0 +7.9%,
p=0.031). In vivo, LPS induced macromolecular leak of FITC-BSA (0.02 g kg-1 i.v.) (LPS: 95.3 (86.7 to 97.9)%,
p=0.043) from post-capillary venules (<40 µm) and increased leukocyte rolling as endotoxemia progressed
(p=0.027), both being reduced by 150 nmol kg-1 UFP-101 (i.v., jugular vein).
Firstly, the rat mesenteric microcirculation expresses NOP receptors and secondly, NOP function (ability to induce
dilation) is enhanced with LPS. UFP-101 also reduced microvascular inflammation to endotoxemia in vivo. Hence
inhibition of the microvascular N/OFQ-NOP pathway may have therapeutic potential during sepsis and warrants
further investigation.
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Introduction
The presence of bacteria in the bloodstream, or sepsis,
results in generalised inflammation of blood vessels,
hypotension and hypovolemia, which together cause tissue
damage and poor perfusion of organs, potentially resulting in
multiple organ failure. In the United States there are an
estimated 20 million annual cases of severe sepsis [1]. With a
mortality rate of 35% this suggests around 700,000 deaths per
year, exceeding mortality rates for breast and colon cancer [1].
Pharmacological treatments remain inadequate therefore it is
of utmost importance to discover new pathways that could be
targeted therapeutically during this potentially fatal condition.
Nociceptin/orphanin FQ (N/OFQ) is an opioid-like peptide
and an endogenous ligand for the NOP receptor (previously
known as ORL1), which is coupled to the Gi/Go signalling
pathway [2]. With the exception of kappa;KOP (very weak)
there is no activity of N/OFQ at classical opioid receptors
(mu;MOP, delta;DOP or KOP [2]). NOP is expressed on aortic
endothelium [3], and following intravenous (i.v.) and
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intracerebroventricular (i.c.v.) administration, N/OFQ caused
both hypotension and bradycardia [4-6]. N/OFQ also increased
aortic blood flow and induced dilation of large blood vessels
>200 µm [4,7]. The cardiovascular effects of N/OFQ are absent
in mouse knockouts for NOP (NOP-/-) [8]. Within smaller blood
vessels (15 to 40 µm) N/OFQ also induces dilation, along with
inflammatory responses such as increased permeability and
leukocyte-endothelial interactions within postcapillary venules
[9]. Furthermore, white blood cells express NOP [10,11], but
NOP expression on the microvascular endothelium has not yet
been directly identified. Our preliminary experiments using
qPCR suggested that protein levels of NOP within the
microcirculation may be too low for analysis of expression via
this technique. Hence we labelled N/OFQ with a fluorescent
marker (fluoroscein isothiocyanate, FITC) to produce FITC-N/
OFQ, which could then be injected locally at high
concentrations to identify the distribution of NOP in small
vessels.
The N/OFQ-NOP pathway may also play a role in sepsis
[12], with plasma N/OFQ concentrations being higher in septic
patients who died within 30 days, compared to survivors [11].
Upregulation of N/OFQ has also been reported in rat sensory
neurones and hypothalamus in response to lipopolysaccharide
(LPS), a component of gram negative bacteria, with antibodies
to the receptor for LPS (toll-like receptor-4; TLR-4) also
preventing induction of N/OFQ by LPS in murine dorsal root
ganglion neurons [13-15]. Nevertheless, studies using isolated
rat splenocyte cells did not detect significantly increased levels
of N/OFQ released from cells until 18 hours of stimulation with
LPS [16]. For this reason, combined with the fact that many
patients are not treated until sepsis is well established, we
studied N/OFQ 20 to 24 hours after the onset of endotoxemia.
Thus far N/OFQ (0.1 mg kg-1, s.c.) has been found to
decrease survival from 30% to 0% at 5 days in the cecal
ligation and puncture (CLP) model of sepsis in rats [17]. In
conjunction with proposed inflammatory role for N/OFQ [2], we
further hypothesised that the function of microvascular NOP-
N/OFQ would be altered in an established LPS model of sepsis
(endotoxemia) [18,19].
Should the NOP-N/OFQ pathway be upregulated during
endotoxemia one would anticipate that manipulating this
pathway could be of therapeutic benefit. Only one study has
previously utilised the selective NOP antagonist [Nphe1,
Arg14,Lys15] N/OFQ-NH2 (UFP-101) [20] during sepsis: in rats,
Carvalho et al. demonstrated that 0.03 mg kg-1 UFP-101
improved survival rates from approximately 30% to 65%. 0.03
mg kg-1 UFP-101 also reduced plasma concentrations of TNF-α
and IL-1β in response to CLP [17], and when given i.c.v.
reduced the hypothalamic pituitary adrenal stress response to
LPS [14]. The current study was important to determine
whether UFP-101 was similarly effective in the LPS model of
sepsis, and whether beneficial effects were reproduced at the
microvascular level.
This study aimed to determine the inflammatory role of
N/OFQ and its receptor NOP (ORL1) within the
microcirculation, along with anti-inflammatory effects of the
NOP antagonist UFP-101 (University of Ferfara Peptide-101) in
an animal model of sepsis (endotoxemia).
Materials and Methods
Animals and Housing
Male Wistar rats (200 to 300 g; Harlan, UK, n=47) were
obtained from the Field Laboratories at the University of
Sheffield, UK. All experiments were performed ethically in
accordance with the UK Home Office, Project Licence number
40/2809. Animals were held in the animal facilities for at least
1 week before experimental procedures, exposed to light on a
12: 12 h cycle in a humidity- and temperature-controlled
environment, maintained on 0.3% sodium, standard, pelleted,
commercial diet and allowed water ad libitum.
Drugs and solutions
The constituents of the HEPES-buffered phosphate saline
(HEPES-PBS) solution were: 0.2884 g l-1 MgSO4, 0.245 g l-1
CaCl2, 2.383 g l-1 HEPES, 8.2983 g l-1 NaCl, 0.3504 g l-1 KCl,
0.1606 g l-1 KH2PO4. On the day of use 0.99 g l-1 of D(+)
glucose was added to the solution and the pH adjusted to 7.4
[21]. Fluoroscein isothiocyanate (FITC) (10%, A1628, Sigma,
UK) was conjugated to bovine serum albumin (66 KDa BSA
(98%), A7030, Sigma) as previously described [22], at 5°C to
avoid denaturing the BSA. N/OFQ and UFP101 were also
prepared in house as previously described [22,23]. All other
drugs were obtained from Sigma unless stated.
Synthesis of [Lys(FITC)18]N/OFQ-NH2 (FITC-N/OFQ)
Synthesis of FITC-N/OFQ (MW: 2895) was performed using
the intermediate [Lys(Dde)18] N/OFQ-NH2 in accordance with
procedures previously reported [23]. Selective deprotection of
the Lys18 side chain was achieved by following the procedure of
Bycroft et al. [24].
300 mg of protected [Lys(Dde)18] N/OFQ-NH2 -resin
suspended in anhydrous tetrahydrofuran (THF, 3 ml) was
added to 2% hydrazine in dimethylformamide (DMF, 5 ml). The
reaction mixture was stirred under argon for 30 min, the
solution filtered and the resin washed 3 times with DMF (5 ml)
and CH2Cl2 (5 ml). To a suspension of protected [Lys(free side
chain)18] N/OFQ-NH2-resin (170 mg, 0.7 meq/gr; 0.12 meq) in
freshly distilled tetrahydrofuran (THF, 3 ml), fluorescein
isothiocyanate isomer I (FITC) (0.2 meq) in THF : absolute Et-
OH (1 : 1, 3 ml) and triethylamine (0.25 ml) was then added.
The solution was stirred in the dark under argon at room
temperature for 12 h. The solution was then filtered and the
resin washed 5 times with THF (5 ml) and 3 times with CH2Cl2
(5 ml). The protected [Lys(FITC)18] N/OFQ-NH2-resin was
treated with reagent B [25], which contained trifluoroacetic acid
(TFA) : H20 : phenol : triisopropylsilane (88 : 5 : 5: 2 v/v; using
10 ml per 0.2 g of resin) for 1.5 h at room temperature in the
dark. After filtration of the resin, the solvent was concentrated
under vacuum and the residue triturated with ether. The crude
peptide was purified by preparative reverse phase HPLC and
lyophilized.
Nociceptin and Sepsis
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Receptor and GTPγ[35S] binding to recombinant opioid
and NOP receptor
Experiments were performed using Chinese hamster ovary
(CHO) cells stably expressing human recombinant MOP, DOP,
KOP and NOP receptor. Selectivity of binding was assessed by
measuring the displacement of [3H] diprenorphine ([3H]DPN)
from membranes prepared from CHO cells expressing MOP,
DOP and KOP or [3H] N/OFQ to membranes prepared from
CHO cells expressing NOP receptors. Endomorphin-1, Leu-
enkephalin, norbinaltorphimine and N/OFQ were included as
reference ligands for MOP, DOP, KOP and NOP respectively.
Data are expressed as % displacement of bound radioligand by
FITC-N/OFQ and the reference compounds. The concentration
of displacer producing 50% displacement of specific binding
was corrected for the competing mass of radioligand according
to Cheng and Prusoff to yield pKi [26], a measure of affinity.
Functional activity of FITC-N/OFQ was assessed by measuring
agonist stimulated GTPγ[35S] binding in membranes prepared
from CHO cells expressing NOP receptors [27]. The
concentration of ligand (FITC-N/OFQ or N/OFQ) producing
50% of the maximum response (Emax, efficacy) is a measure of
potency (EC50). All analysis was performed using GraphPad
Prizm V4.0.
Intravital microscopy (IVM)
Surgery.  Rats were anesthetised with thiopental (induction,
30 mg kg-1; maintenance, 40-90 mg kg-1 h-1; Intra-Vital Sodium,
Rhone-Poulenc Rourer, West Malina, UK) to prepare the
mesentery for fluorescent IVM [9]. The right jugular vein was
cannulated for administration of FITC-BSA and the left carotid
artery was cannulated for computerised recording of mean
arterial pressure (MAP) using WINDAQ (DI-400, DATAQ
Instruments, Akron, OH, USA).
Image analysis.  Images were monitored using a CCD
camera (TK-C13060B, JVC, UK) displayed on a high-resolution
monitor (PVM-14N5MDE, Sony, UK) and recorded on to CD-
RW using a DataVideoTM CD recorder (VDR-3000, Holdan Ltd,
UK) for later off-line computerised image analysis
(CapiscopeTM, KK Technology, UK) as previously described
[19]. Prior to experimentation a 30 minute equilibration period
was allowed (T-60-T-30), during which time one area of interest
containing an arteriole (15 to 40 µm) and venule (25 to 70 µm)
was selected with transmitted light for the purposes of image
analysis. At T-30 FITC-BSA (IVM, Study B) also was given via
the jugular vein (0.2 g kg-1) to allow fluorescent images to be
obtained every 10 minutes during experimentation. At each
time point the maximum exposure to blue light (460 to 490 nM)
was <60 seconds to prevent photoactivation and tissue
damage [28].
To measure receptor binding or macromolecular leak
CapiscopeTM assigned an integer value to the brightness of the
fluorescence based on an 8-bit arbitrary gray scale ranging
from 0 (black) to 255 (white), with fixed brightness and contrast
levels. Receptor binding (IVM, Study A) was assessed in each
animal by using Capiscope to place a box at three sites where
‘hot-spots’ of receptor binding could be seen. Macromolecular
leak (Study B) was measured at three points within the
interstitium adjacent (<2 mm) to a randomly selected
postcapillary venule, Rolling leukocytes were assessed within a
relatively straight length of vessel, using transmitted light, by
counting the numbers that passed a fixed point over 30
seconds [9].
Experimental groups.  In study A the mesenteric artery was
also cannulated to administer FITC-N/OFQ (200 nM kg-1, 40
nM) intra-arterially at T0 (n=5). Images of the microcirculation
were then recorded continuously for 60 seconds, which was
the duration of visible fluorescence. At the following time point
(T-15), unlabelled N/OFQ (200 nM kg-1, 40nM) was administered
15 seconds before 200 nM kg-1 FITC-N/OFQ in order to occupy
the NOP receptor site.
In study B animals received LPS (Serotype B5: 055) or the
equivalent volume of saline (0.1ml 100g-1) into the tail vein at
-24 h (1 mg kg-1) and -2 h (0.5 mg kg-1) prior to experimentation
(T0) in (i) control, n=6; (ii) LPS, n=6, (iii) UFP-101, n=6 and (iv)
LPS + UFP-101, n=6 groups. Animals received UFP-101 (150
nM kg-1, 62.5nM), or the equivalent volume of saline (1 ml kg-1)
into the jugular vein at the baseline recording (T0). Images of
the microcirculation were recorded for 60 seconds with
transmitted light and 30 seconds with blue light (460-490nM)
every 10 minutes at T10, T20, T30 and T40. A full response curve
was thus constructed, but data are shown graphically only at
T40 for ease of interpretation as similar patterns of response
were observed at earlier time points.
At the end of the procedure rats were killed humanely in
accordance with UK Home Office procedure using an overdose
of anesthetic followed by cervical dislocation.
Pressure myography
Surgery.  Rats were killed in accordance with UK Home
Office requirements involving cervical dislocation. This was
followed by rapid removal of the ileum and adjacent mesentery
from either control or LPS-treated animals. The mesentery was
placed in HEPES-PBS solution at 4°C and a third order artery
(~200µm) dissected free from surrounding adipose tissue.
Vessels were carefully transferred to the organ bath and
mounted on glass cannulae at 60mmHg (Living Systems
Instrumentation, Burlington, Vermont, USA). Vessels were
stabilised and maintained as previously described, with the
Living Systems video dimension analyser used to determine
luminal diameters21. In previous studies it has been determined
that rat mesenteric vessels do not respond to abluminal N/
OFQ, hence N/OFQ was administered intraluminally using pre-
determined doses [9].
Experimental groups.  Animals were divided into either (i)
control (n = 6); (ii) N/OFQ (n = 6) or (iii) LPS + N/OFQ (n = 6)
treated groups. LPS was administered into the tail vein at -24 h
(1mg kg-1) and -2 h (0.5mg kg-1) (iii), or the equivalent volume
of saline (1ml kg-1) (i, iii), and then mesenteric tissue removed
after 24 h of endotoxemia. Vessels were also exposed to 50 µg
ml-1 LPS (Serotype B5: 055) in the organ bath for the duration
of myography.
After performing a concentration response curve with
U46619 (10-10 to 10-6M), all vessels were pre-constricted with
an EC80 of U46619 (2x10-7M). U46619 is synthetic analogue of
prostaglandin H2 which acts as a thromboxane A2 receptor
agonist and commonly used in myography to pre-constrict
Nociceptin and Sepsis
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isolated vessels before studying vasodilator responses. Thus
following pre-constriction at a constant pressure (60 mmHg)
HEPES (i, iii) or the calculated EC80 dose of N/OFQ (10-5M) (ii)
was then allowed to flow through the lumen of pre-constricted
vessels for 20 minutes at a flow rate of 15 µl min-1 [9].
Measurements of luminal diameter were taken every minute,
but data are shown such that the percentage change in the
diameters of vessels is reported between T0 and T20. At the end
of the protocol, the organ bath was washed out and
acetylcholine (ACh, 10-5M) was added to pre-constricted
vessels to ensure that endothelial integrity had been
maintained.
Statistics
Parametric data are presented as mean (+SEM), with
statistical analysis performed using two-way ANOVA or student
t-test. However, all in vivo data were non-parametric and
presented as median and interquartile ranges (25th to 75th), with
n = 5 or 6 animals used in each group, as determined using
preliminary data. Data are expressed as box and whisker plots,
except where negative values were present within data and this
was not possible. In study A paired data were analysed using
the Wilcoxon paired signed rank test at equivalent time points.
In study B, if Kruskall-Wallis test identified significant
differences between groups, analyses was performed using the
Mann-Whitney U-test. Likewise, comparing data to baseline, if
the Freidman test identified a significant difference then the
Wilcoxon signed ranks test was performed. To avoid
significance being obtained due to multiple tests, only one time
point underwent statistical evaluation using post-hoc tests. All
statistical analysis was undertaken by an independent
statistician using SPSS version 16.0. Results were considered
statistically significant at p < 0.05.
Results
Preliminary characterisation of FITC-N/OFQ
In receptor binding experiments FITC-N/OFQ showed high
affinity (pKi 9.60 compared to 9.85 for N/OFQ) for NOP and at
least 4000 fold selectivity over KOP (Figure 1A). As anticipated
the high affinity binding of FITC-N/OFQ resulted in a high
potency stimulation of the binding of GTPγ[35S] to membranes
prepared from cells expressing NOP (Figure 1B). There was no
difference in potency (pEC50 ~8.4) or efficacy (Emax: 4.7 to 5.2
expressed as stimulation factor) between the native peptide
and FITC-N/OFQ. Based on this simple in vitro characterisation
FITC-N/OFQ does not differ substantially from native N/OFQ in
terms of affinity, selectivity, functional potency and efficacy
indicating its suitability for use in the in vivo experiments
described below.
Evidence for N/OFQ specific binding within mesenteric
microcirculation
In vivo, FITC-N/OFQ bound to specific sites on the
endothelium of arterioles, indicating sparse distribution of NOP
receptors in the mesentery in control conditions (Figure 2). This
binding appeared to be specific, as N/OFQ prior to FITC-
N/OFQ (competing for the same receptor site) reduced the the
ability to bind at these sites (Figures 2 and 3).
Figure 1.  Characterisation of FITC-N/OFQ (F-N/OFQ) at
recombinant NOP and classical opioid receptors on CHO
cells.  A: Binding affinity of F-N/OFQ and a range of opioid
receptor subtype selective reference compounds. F-N/OFQ
shows high selectivity for NOP over classical opioid receptors
(mean (range) of up to 4 experiments.) *curves did not saturate
Ki estimated between 1 and 10µM. B: Both N/OFQ and F-
N/OFQ behave as full agonists on recombinant human NOP.
These data are stimulation factor = agonist stimulated specific
binding / basal specific binding (mean +SEM, n=8).
doi: 10.1371/journal.pone.0074943.g001
Figure 2.  Representative images of rat mesenteric
arterioles and venules 5 seconds after injection of 200 nM
kg-1 FITC-N/OFQ into the mesenteric artery with (C,D) and
without (A,B) N/OFQ (added 15 sec prior to FITC-N/OFQ
and labelled T15) competing for the same NOP receptor
site.  The areas highlighted by arrows indicate binding of FITC-
N/OFQ to NOP (FITC-N/OFQ-NOP) and thus sparse
distribution of NOP receptors on the endothelium in this animal.
doi: 10.1371/journal.pone.0074943.g002
Nociceptin and Sepsis
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Cardiovascular and microvascular effects of N/OFQ
In vivo, dose dependent hypotension, dilation of mesenteric
arterioles and venules, along with macromolecular leak were
observed with N/OFQ in agreement with previous studies (data
not presented)9. In addition, pressure myography demonstrated
that N/OFQ caused isolated arterioles to dilate by 32.6 +8.4%,
compared to only 6.8 +3.8% in controls (p=0.031).
Altered responses to N/OFQ during LPS administration
Cardiovascular.  LPS caused a significant increase in heart
rate (T40, p=0.004), but this was not altered by the addition of
UFP-101 (p=0.004, Figure 4). LPS also caused hypotension
compared to controls (T40, control: 105 (95 to 110) mmHg; LPS:
85 (83 to 103) mmHg) (Figure 4), but this did not reach
significance (p=0.429).
Figure 3.  The decay of FITC fluorescence (gray level) in
the endothelium of rat mesenteric arterioles and venules
over 60 seconds in response to 200 nM kg-1 FITC-N/OFQ
(F-N/OFQ), with (T-15, open circles) and without (T0, closed
circles) 200nM.kg-1 N/OFQ (n=5 animals).  Values are
median, with upper and lower error bars representing the 75th
and 25th percentiles respectively. The time courses were
significantly different.
doi: 10.1371/journal.pone.0074943.g003
UFP-101 alone also caused an increase in heart rate (T40,
control: 330 (308 to 330) bpm, UFP-101: 375 (360 to 390)
bpm) (Figure 4, p=0.04), but had no significant effect on MAP.
Microvascular.  Pressure myography demonstrated that
LPS enhanced dilation of isolated arterioles to 10-5M N/OFQ,
as arterioles in the N/OFQ + LPS group dilated by 62.0 +7.9%
compared to 32.6 +8.4% with N/OFQ alone (p=0.031).
Venules appeared dilated slightly in LPS-treated animals
compared to controls (T40, control: 19.1 (17.8 to 20.8) µm, LPS:
29.1 (24.2 to 31.8) µm) (Figure 5, p=0.002), but diameter
changes in arterioles were not significant (p=0.057) (Figure 5).
LPS caused significant increases in both macromolecular
leak and leukocyte rolling (leak, p=0.043; rolling, p=0.027), that
Figure 4.  The effect of UFP-101 on cardiovascular
variables: mean arterial pressure (MAP, mmHg; upper
panel) and heart rate (beats per minute, bpm; lower panel)
were measured in anesthetised rats at baseline (T0), this
being 24 hours after i.v. injection with 1 mg kg-1 + 0.5 mg
kg-1 (LPS, n=6; LPS + UFP-101, n=6) or saline (control, n=6;
UFP-101, n=6).  Measurements were repeated 40 minutes
after baseline (T40) in response to i.v. injection of 150 nM kg-1
UFP-101 (LPS + UFP-101, UFP-101 groups) or saline (control;
LPS, groups). Values are median, with open bars representing
the 50th-75th percentile, grey bars the 25th-50th percentile and
upper and lower error bars representing the maximum and
minimum respectively.
doi: 10.1371/journal.pone.0074943.g004
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were significantly different from controls (T40, leak: controls, 5.3
(-5.9 to 11.8) versus LPS: 95.3 (86.7 to 97.9)%, p=0.008 and
rolling: controls, 3.0 (0.8 to 3.8) versus LPS: 7.0 (4.8 to 10.8)
per min, p=0.003). Macromolecular leak and leukocyte rolling
to LPS were reduced by co-administration of 150nmol.kg-1
UFP-101 (T40, leak: -34.9 (-63.2 to -15.1)% and rolling: 0 (0 to
1) per min), such that they were no longer significantly different
from controls (leak, p=0.063; rolling, p=0.117) (Figure 6).
With UFP101 arterioles (T40, controls: 16.2 (10.9 to 17.7) µm;
UFP-101: 7.1 (6.3 to 8.6) µm) (p=0.004) and venules (controls,
19.1 (17.8 to 20.8) µm; UFP-101: 9.7 (8.4 to 12.1) µm)
(p=0.001) (Figure 5) appeared constricted compared to
controls however, differences between controls and UFP-101
groups were also observed initially between the groups (T40,
arterioles: p=0.004; venules: p=0.001). UFP-101 had no effect
Figure 5.  The effect of UFP101 on microvessel diameters
in vivo: arteriole (upper panel) and venule (lower panel)
diameters were measured in anesthetised rats at baseline
(T0), this being 24 hours after i.v. injection with 1 mg kg-1 +
0.5 mg kg-1 (LPS, n=6; LPS + UFP-101, n=6) or saline
(control, n=6; UFP-101, n=6).  Measurements were repeated
40 minutes after baseline (T40) in response to i.v. injection of
150 nM kg-1 UFP-101 (LPS + UFP-101, UFP-101 groups) or
saline (control; LPS, groups). Values are median, with open
bars representing the 50th-75th percentile, grey bars the
25th-50th percentile and upper and lower error bars representing
the maximum and minimum respectively.
doi: 10.1371/journal.pone.0074943.g005
on either macromolecular leak or leukocyte rolling (leak,
p=0.151; rolling p=0.394).
Discussion
This study has demonstrated that UFP-101 exhibits anti-
inflammatory properties within the microcirculation, specifically
it reduced macromolecular leak and leukocyte rolling, this
potentially being an important contributor to reduced mortality
in septic animals treated with UFP-10117. Increased blood
volume is the basis of current therapeutic strategies, and
Figure 6.  The effect of UFP-101 on macromolecular leak
and leukocyte rolling in vivo: macromolecular leak
(percentage change in interstitial FITC-BSA fluorescence
from baseline, upper panel) and leukocyte rolling (per
minute, baseline and after treatment, lower panel) in post
capillary venules (<40 µm) within the anesthetised rat
mesentery preparation.  Measurements were taken in
response to i.v. injection of 150 nM kg-1 UFP-101 (LPS +
UFP-101 and UFP-101 groups) or saline (control and LPS
groups). Values are median, with open bars representing the
50th-75th percentile, grey bars the 25th-50th percentile and upper
and lower error bars representing the maximum and minimum
respectively. *increased compared to control.
doi: 10.1371/journal.pone.0074943.g006
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achieving this via reducing microvessel permeability, in turn
increasing blood flow and organ perfusion, confirms promising
therapeutic potential for NOP antagonists.
Using a range of complementary experiments and a novel
fluorescent analogue of N/OFQ our data also suggested that
NOP receptors are expressed on small foci of microvascular
endothelium of rat mesentery. This is in agreement with
expression of NOP previously reported on the endothelium of
larger blood vessels, namely rat aorta [3]. Nevertheless, the
present data suggest that expression may be quite sparse in
these small vessels. This has functional consequences for
NOP partial agonists as they may then behave as antagonists
[29]. In conjunction with previous studies, identification of NOP
receptors within the microcirculation was an important
foundation for understanding how UFP-101 exerted beneficial
effects during endotoxemia.
Perhaps the most important part of the study was the
therapeutic potential of UFP-101 in an LPS model of sepsis. In
agreement with previous observations, that UFP-101 was anti-
inflammatory during CLP [17], we also determined that
UFP-101 reduced macromolecular leak and reduced leukocyte
rolling at the later time point in response to LPS. Furthermore,
UFP-101 reduced vasodilation of venules in response to LPS,
often associated with excessive production of pro-inflammatory
cytokines. Effects on arterioles, which regulate blood pressure,
were not observed, but mesenteric venules did respond to LPS
in agreement with our previous studies at 0 to 4 h [30]. This
may be a compensatory mechanism to preserve blood flow to a
vital organ. In conjunction with known reductions in pro-
inflammatory cytokines, the ability of UFP-101 to reduce
microvascular inflammation may relate to the beneficial effects
on mortality during CLP [17]. In agreement, there are increased
plasma levels of N/OFQ in patients who die from sepsis versus
those who do not [31]. Moreover in a very recent study tracking
the time course of sepsis in patients on the intensive care unit
we have data demonstrating an increase in plasma N/OFQ
levels that falls when the patients recover (in this context
patients are their own controls) (Thompson, Serrano-Gomez,
McDonald, Ladak, Bowrey and Lambert, 2013, unpublished).
Of note however, our animal model of sepsis was not
particularly severe, as all animals survived the duration of the
experiment with hypotension <20%. Whilst non-lethal endotoxin
models of sepsis reflect more accurately the insidious onset of
the disease, ultimately septicemia is a disease involving the
entry of live bacteria, such as E. Coli into the bloodstream. In
CLP models which reflect this, mortality rates are high: for
example the study by Carvalho et al. demonstrated a 70%
mortality rate [17]. It is thus re-assuring that these present data
with LPS are in agreement with this study. With i.v.
administration of UFP-101 we also discovered no reversal of
the tachycardia or mild hypotension induced by LPS. This
finding is in agreement with direct NOP-N/OFQ inflammatory
effects on the microcirculation, but not blood pressure, being a
locally mediated mechanism involving histamine [9].
In addition to macromolecular leak, dilation of isolated
arterioles (~200µm), was certainly increased by exposure to
LPS. This suggests that the function of NOP is enhanced
during exposure to LPS; further studies are required to confirm
this in smaller vessels in vivo and determine the mechanism by
which LPS increases NOP expression and/or intracellular
signalling. We could not repeat the FITC-N/OFQ experiments
in LPS-treated animals, as macromolecular leak interfered with
the fluorescent measurements. Interestingly our initial attempts
with immunohistochemistry to reproduce the study performed
by Granata et al. on the aortic endothelium were unsuccessful
using sections of mesenteric microcirculation [3]. This may be
because expression is sparse (Figure 2) and radioligand
binding studies with [3H] UFP-101 are complicated by low
radioligand specific activity [32].
To develop this point further, a major criticism of our work
might be that we have not demonstrated the presence of NOP
using more conventional techniques; (i) radioligand binding and
(ii) Western blotting. Due to the very small amount of tissue
that can be harvested from the vasculature and the presumed
ultra-low expression it was not possible to perform a standard
binding experiment of the type shown in Figure 1, even if we
employed a high specific activity radioligand ([125I] N/OFQ) [33].
The amount of tissue may have been sufficient for Western
blotting but, as with most members of the opioid family, there
are no selective antibodies for use [34]. In the absence of
these, our functional data provides strong evidence for
functional NOP and, to reiterate, the completely novel
approach used in our present work (FITC-N/OFQ)
demonstrated sparse expression in the microvasculature which
would not have been possible by other means.
One further limitation of this study is that control animals may
have experienced a degree of unavoidable inflammation at
baseline, due to the surgery required for observation of the
microcirculation using intravital microscopy. In addition, our
cardiovascular (and microvascular variables) differed at
baseline in all treated groups because animals were already
‘septic’. Indeed, an important limitation of studies using
anesthesia/surgery and IVM to observe the mesenteric
microcirculation, is that it is not possible to integrate a non-
septic baseline or an unanesthetised control. Nevertheless, if
there was some degree of inflammation at baseline due to
surgery, these data demonstrated that it was reduced in the
presence of UFP-101.
Despite the interesting data with inflammatory markers, we
could not make firm conclusions as to whether intravenously
administered UFP-101 given to non-septic animals truly caused
microvascular constriction, as we are uncertain whether this
observation was due to differences in the diameter of vessels
at baseline or an immediate effect of UFP-101. Despite this, as
part unpublished data within previous studies we also observed
vasoconstriction with UFP-101 [9]. Compared to larger blood
vessels the mesenteric microcirculation as studied here (<40
µm) receives little neural control [35]. Thus, regardless of the
baseline status vascular diameters a NOP dependent (rather
than neural) mechanism must be engaged for constriction to
occur via UFP-101. Taken together with our data utilising
isolated vessels and N/OFQ, it is possible that NOP receptors
may regulate vessel diameters via endothelial as well as
central/neural control mechanisms, as we have alluded to in
previous studies proposing an endothelial NOP-histamine
pathway [9].
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In this study intra-arterially administered UFP-101 had no
effect on MAP, similar to studies whereby UFP-101 was given
i.c.v. to mice [36]. Further studies likewise reported no
differences in MAP between NOP-/- and wild-type mice [8].
However, our findings of tachycardia are in contrast to
Burmeister & Kapusta [36]. Nevertheless, similar to our data,
300 pmol UFP-101 injected into the paraventricular nucleus
(PVN) of the hypothalamus caused increased heart rate and
renal sympathetic nerve activity in conscious Sprague-Dawley
rats, along with a non-significant increase in MAP [37]. In our
previous studies we did not report the effects of UFP-101 over
time, rather its effects on cardiovascular response to N/OFQ
[9]. Thus in conjunction with the literature, our new evidence
with UFP-101 suggests that the vascular mechanisms of NOP
are multifactorial, differing between species and the organ of
interest. N/OFQ may also have opposing effects depending
upon the route via which it is administered.
At a cellular level activation of NOP will reduce cAMP
formation, close voltage gated Ca2+ channels and open K+
channels to produce hyperpolarisation. In a neurone this
combination of events is easy to collate into an inhibition of
neurotransmission. In addition to these classical signalling
events there is also evidence of increased MAP kinase activity
[2]. We do not know how these events transfer to the vascular
endothelium, but a modulation of the driving force for dilation
(increased Ca2+, NO activation or cAMP generation) would
seem likely targets and these will need rigorous experimental
verification in further studies.
In conclusion, we have evidence that the endothelium of the
rat mesenteric microcirculation expresses NOP receptors.
Furthermore, in agreement with previous studies using a cecal
ligation model, UFP-101, a selective antagonist of NOP,
reduces microvascular inflammation during an LPS model of
sepsis in rats. Animal studies with small data sets should be
considered as preliminary data and thus clinical studies would
now be useful to determine if this potentially beneficial
therapeutic effect could translate into humans.
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